

Molecular Pathology Center, Lady Davis Institute/Jewish General Hospital, Montreal

Tel: (514) 340-8222 # 23120 (Molecular Pathology), Fax: (514) 340-8134

	<h2 style="margin: 0;">Requisition for Molecular Pathology</h2> <h1 style="margin: 0;">Urothelial Carcinoma FGFR Testing</h1>
---	---

<p>Requesting physician: Name: Dr. _____ Institution: _____ Department: _____ Address: _____ City, postal code: _____ Tel: () - _____ Fax: () - _____</p> <p>The fax number is mandatory and will be used to send the results</p> <p>Copy to: Dr. _____ Fax: () - _____ Dr. _____ Fax: () - _____</p>	<p>Patient: Name: _____ Given name: _____ D.O.B.: _____ / _____ / _____ (yyyy/mm/dd) Sex: <input type="checkbox"/> M <input type="checkbox"/> F JGH registration #: _____ RAMQ #: _____</p>				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">For laboratory use</td> <td style="width: 50%;"></td> </tr> <tr> <td style="height: 40px;"></td> <td></td> </tr> </table>		For laboratory use			
For laboratory use					

Sample

Date of procedure: _____ / _____ / _____ (yyyy/mm/dd) Hospital of procedure city: _____

Paraffin block (including cell block) Block ID #: _____

FFPE sections (According to specimen requirements)

Type of specimen: Surgical resection Biopsy, core biopsy Transurethral resection of bladder tumour (TURBT)

Tumour Cellularity: _____ **Note:** TURBT specimens require the deep/ invasive part of tumor

Include the original pathology report with this requisition for all test requests

Send request and samples to: Jewish General Hospital Pathology, Room E603 3755 Côte-Sainte-Catherine Road Montreal, QC H3T 1E2	Physician's signature: _____	Date of request: _____ (yyyy/mm/dd)
--	------------------------------	--

Samples received without this requisition will **NOT** be processed

Date and time:	Institution:	Block ID #:	Block(s):	Slides(s):	Initials:

Specimen Requirements and Shipping Guidelines –BALVERSA™ (erdafitinib) Diagnostic *FGFR* Genetic Testing

Role of *FGFR* gene testing in bladder cancer:

Mutations in fibroblast growth factor receptors (*FGFRs*) have been shown to play a role in bladder cancer, and is linked to tumor growth, metastasis and overall prognosis. BALVERSA™ (erdafitinib) is a kinase inhibitor that binds to and inhibits *FGFR* enzymatic activity. It is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC), whose tumours have susceptible *FGFR2* or *FGFR3* genetic alterations and who have disease progression during or following at least one line of prior chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy. Testing is performed using a pan-cancer NGS panel which analyzes both DNA and RNA and can detect sequence changes as well as rearrangements involving *FGFR1*, *FGFR2*, *FGFR3* and *FGFR4*. The clinical trials had enrolled UC patients with pre-specified *FGFR* alterations: any of the following ***FGFR* missense mutations (p.Arg248Cys, p.Ser249Cys, p.Gly370Cys, p.Tyr373Cys)** or ***FGFR2/3* gene fusions (*FGFR3-TACC3*, *FGFR3-BAIAP2L1*, *FGFR2-BICC1*, *FGFR2-CASP7*)**

Webinar link: *FGFR* Testing in Bladder Cancer: Co-Presented by Dr. Alan Spatz (JGH) and Dr. Shamini Selvarajah (UHN)

https://zoom.us/rec/share/48hqEbX-63tOYpX97WvQXJwgEJT6eaa81Xld_cPyUek1c35DeGbZtmiaMUjy7sO

Specimen Requirements:

- When possible, the FFPE block is preferred; a ~3mm area will be cored from the block. If a block cannot be sent, please send tissue sections on uncoated air-dried slides shipped at room temperature (8 unstained sections at 7um). Please submit 15 sections for small biopsies. For core biopsies, the entire block is required.
- Tumour cellularity must be > 20% tumor cells for accurate test results
- **EXTERNAL pathology review and corresponding circled H&E slide required prior to sending block**
- For all tissue sections, we require 2 H&E stained sections, one cut before cutting slides from the block and one cut after serial sectioning
- Please note that for transurethral resection of bladder tumour (TURBT) specimens, it is the deep/ invasive part of the tumor rather than the superficial layer that should be tested [PMID: 27091807]
- PLEASE NOTE: **Tumour cellularity must be indicated on the requisition**

Shipping Requirements:

- Samples should be appropriately labelled and shipped according to these instructions:
- The slides must be shipped to reach the laboratory immediately after sectioning, preferably in an airtight container
- Each slide must be labelled with the patient's name, date of birth and MRN#
- Complete the site-specific clinical requisition form
- Place the slides in an appropriate protective package
- Insert the package in a biohazard plastic bag
- Place the biohazard bag, and completed requisition, into an appropriate outer container for shipping and label the outer container with a biohazard label
- Send to the following address using appropriate methods (FedEx, courier or similar):

Shipping Address:

Jewish General Hospital
Molecular pathology Centre, Room E603
3755 Cote St Catherine Road
Montreal, Quebec H3T 1E2
Phone: (514) 340-8222 ext. # 23120

All Specimens that DO NOT MEET the above specimen and shipping requirements will be REJECTED